Editorial Share on Navigating the Evolving Landscape of EGFR-Mutated NSCLCAuthor: Roy S. Herbst, M.D., Ph.D.Author Info & AffiliationsPublished December 29, 2025N Engl J Med 2026;394:87-91DOI: 10.1056/NEJMe2514042VOL. 394 NO. 1Copyright © 2026 PermissionsFor permission requests, please contact NEJM Reprints at [email...
Targeted Therapy In A Shot: New Approval for EGFR-Mutated Lung Cancer Can Improve Day-To-Day Life For Patients Rybrevant Faspro For Non-Small Cell Lung Cancer (NSCLC)A subcutaneous version, or a version that can be given as a shot rather than an...
MicrocirculationVolume 33, Issue 1 e70047 ORIGINAL ARTICLE Aggregation of Platelets and Human EGFR Mutant Lung Adenocarcinoma Cells Under Flow Is Governed by Shear Accumulation Xiaoxi Sun, Corresponding Author Xiaoxi Sun sunxiaoxi@gdph.org.cn orcid.org/0000-0002-3438-1425 Department of Medical Research, Guangdong Provincial People's Hospital,...
随着精准医学的发展，表皮生长因子-酪氨酸激酶抑制剂（EGFR-TKI）已成为...
Sophora japonica L. is a commonly used traditional Chinese medicine. Sophoricoside (Sop), the isoflavone glycoside obtained in Sophora japonica L., is demonstrated with various pharmacological activities, such as anticancer, anti-inflammation, and immunosuppression. To data, there is a lack of comprehensive...
Original Article Share on Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLCAuthors: Pasi A. Jänne, M.D., Ph.D., David Planchard, M.D., Ph.D., Kunihiko Kobayashi, M.D., Ph.D., James Chih-Hsin Yang, M.D., Ph.D., Ying Liu, M.D., Natalia Valdiviezo, M.D., Tae Min Kim,...
Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key first-line questions clinicians face in today’s landscape This transcript has been edited for clarity. Hello. It's Mark Kris, from Memorial Sloan...
